Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 71335-1819

7 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71335-1819). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl713351819)

Label (Lbl713351819)
Label for Rizatriptan Benzoate 10 mg orally disintegrating tablets (ODT) packed by Bryant Ranch Prepack in Burbank, CA. The label states the product compares to Maxalt 10 mg ODT blister pack by Aurobindo Pharma Limited. It includes storage instructions and a barcode, with the NDC 71335-1819.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours post-dose. The graph compares placebo, Rizatriptan Benzoate 5 mg tablets, and Rizatriptan Benzoate 10 mg tablets over time, with response probabilities increasing from 0% to about 70% at 2 hours for the 10 mg dose.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
A Kaplan-Meier plot showing the estimated probability of patients taking a second dose of rizatriptan benzoate tablets or other migraine medication over 24 hours following the initial treatment dose. The graph compares placebo, rizatriptan benzoate 5 mg, and 10 mg tablets, displaying the probability of remediation or rescue on the vertical axis and hours post-dose on the horizontal axis.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
A line graph titled 'Estimated Probability of Achieving an Initial Headache Response with Rizatriptan Benzoate Orally Disintegrating Tablets by 2 Hours in Pooled Studies 5 and 6.' The x-axis represents hours post-dose (0 to 2), and the y-axis shows the estimated probability of response (0% to 100%). Three lines indicate placebo, Rizatriptan Benzoate OD Tablets 5 mg, and Rizatriptan Benzoate OD Tablets 10 mg, showing increasing probabilities of headache response over time, with the 10 mg dose achieving the highest probability by 2 hours.*
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)
A Kaplan-Meier curve illustrating the estimated probability of patients taking a second dose of Rizatriptan Benzoate Orally Disintegrating Tablets 5 mg, 10 mg, or placebo over 24 hours post-initial dose for migraine treatment. The y-axis shows estimated probability of remedication, and the x-axis shows hours post-dose from 0 to 24.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
A line graph titled 'Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7' compares Rizatriptan Benzoate OD tablets versus placebo. The y-axis shows percent with 95% confidence interval (0 to 100%), and the x-axis shows hours post dose (0.5 to 2.0 hours). Rizatriptan Benzoate OD tablets show increasing percentages over time, higher than placebo, with plotted error bars.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)
Chemical structure diagram showing the molecular formula of the active ingredient Rizatriptan Benzoate, featuring a complex aromatic and nitrogen-containing ring system with a benzoic acid group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.